Schizophrenia News and Research

Latest Schizophrenia News and Research

Jails are holding increasing numbers of mentally ill

The Atlanta Journal-Constitution reports that in Georgia more mentally ill people are locked away than are treated in state psychiatric hospitals. In other state news about mental health, Florida seeks to recoup $4 million from company that managed Medicaid mental health services, and Milwaukee considers bolstering services.

30 Sep 2011

AstraZeneca settles SEROQUEL XR patent infringement litigation

AstraZeneca today announced it has entered into a settlement agreement in its U.S. SEROQUEL XR patent infringement litigation against Handa Pharmaceuticals, LLC regarding Handa's proposed generic version of AstraZeneca's SEROQUEL XR extended-release tablets.

30 Sep 2011

New report finds little evidence to support off-label use of atypical antipsychotics

There is little evidence to support the use of atypical antipsychotic drugs for some treatments other than their officially approved purposes, even though many clinicians continue to commonly prescribe these drugs for so-called "off label" uses, according to a new report from the U.S. Department of Health and Human Services' (HHS) Agency for Healthcare Research and Quality.

29 Sep 2011

Experts to explore implications of mental disorders at 12th EMBL | EMBO conference

You are invited to attend the 12th joint EMBL | EMBO Science and Society Conference - Making sense of mental illness: biology, medicine and society. The conference takes place 4-5 November 2011 at the EMBL Advanced Training Centre, Heidelberg, Germany. Press registration is free.

28 Sep 2011

UCSF neuroscientist wins PECASE award for research into addiction

Linda Wilbrecht, PhD, a neuroscientist at the Ernest Gallo Clinic and Research Center at the University of California, San Francisco (UCSF), is one of 94 researchers named today by President Obama as a recipient of the Presidential Early Career Awards for Scientists and Engineers (PECASE).

28 Sep 2011

Benefits and harms vary among atypical antipsychotics for off-label use

A review of previous studies suggests that even though atypical antipsychotic medications are commonly used for off-label conditions such as behavioral symptoms of dementia, anxiety, and obsessive-compulsive disorder, these medications are effective for only a few off-label conditions, and that the benefits and harms of these medications for these uses vary, according to an article in the September 28 issue of JAMA.

28 Sep 2011

BioLineRx's BL-1020 Phase IIb EAGLE trial data on schizophrenia to be presented at ECSR

BioLineRx, a biopharmaceutical development company, today announced that data from the successfully completed Phase IIb EAGLE study of BL-1020, a first in class GABA-enhanced antipsychotic for the treatment of schizophrenia, will be presented at the 3rd European Conference on Schizophrenia Research (ECSR) held in Berlin, Germany.

28 Sep 2011

Afraxis to participate in NIH's Therapeutics for Rare and Neglected Disease Program

Afraxis, a San Diego-based biotechnology company developing drugs to treat rare genetic diseases through the modulation of p21-activated kinase (PAK), announced today that it has been selected to participate in the National Institutes of Health's (NIH) Therapeutics for Rare and Neglected Disease (TRND) Program.

27 Sep 2011

High consumption of caffeinated coffee appears to reduce risk of depression in women

The risk of depression appears to decrease for women with increasing consumption of caffeinated coffee, according to a report in the September 26 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

27 Sep 2011

Common genetic variants linked to schizophrenia and bipolar disorder

Knowledge about the biological origin of diseases like schizophrenia, bipolar disorder and other psychiatric conditions is critical to improving diagnosis and treatment.

22 Sep 2011

Cornell researchers identify how T. gondii controls host's immune system

Toxoplasma gondii parasites can invade your bloodstream, break into your brain and prompt behavioral changes from recklessness to neuroticism. These highly contagious protozoa infect more than half the world's population, and most people's immune systems never purge the intruders.

22 Sep 2011

Common DNA variations contribute to schizophrenia, bipolar disorder

A team of over 250 researchers from more than 20 countries have discovered that common genetic variations contribute to a person's risk of schizophrenia and bipolar disorder.

20 Sep 2011

Scientists discover common genetic variants associated with schizophrenia and bipolar disorder

Common genetic variants contribute to the risk of schizophrenia and bipolar disorder, an international research consortium has discovered.

19 Sep 2011

Aestus to develop ATx09-002 for treatment of neuropathic pain

Aestus Therapeutics, Inc. and Prosidion Ltd., a wholly owned subsidiary of Astellas Pharma Inc., announced today a license agreement providing Aestus with exclusive, world-wide rights to the Prosidion investigational product PSN-357.

19 Sep 2011

Alkermes establishes business operations in Ireland

Alkermes plc today announced the establishment of its corporate operations in Ireland, with new headquarters located in Dublin. The company, including its headquarters and operations in Athlone, County Westmeath, has more than 450 employees based in Ireland and more than 1,200 employees worldwide.

19 Sep 2011

Researchers confirm strong bidirectional relation between epilepsy, schizophrenia

Researchers from Taiwan have confirmed a bidirectional relation between schizophrenia and epilepsy. The study published today in Epilepsia, a journal of the International League Against Epilepsy (ILAE), reports that patients with epilepsy were nearly 8 times more likely to develop schizophrenia and those with schizophrenia were close to 6 times more likely to develop epilepsy.

19 Sep 2011

Landmark international study confirms common genetic contribution to mental illness

An international research consortium has confirmed that common genetic variants contribute to a person’s risk of schizophrenia and bipolar disorder. The largest study of its kind provides new molecular evidence that 11 regions have strong association with these diseases, including six regions not previously observed. The researchers also found that many of these DNA variations contribute to both diseases. The findings, reported by the Psychiatric Genome-Wide Association Study Consortium (PGC) and published online in two papers in the journal Nature Genetics, represent significant advances in the understanding the causes of these severe and often debilitating disorders.

18 Sep 2011

Alkermes completes merger with Elan Drug Technologies

Alkermes plc and Elan Corporation, plc today announced the completion of the merger between Alkermes, Inc. and Elan Drug Technologies (EDT), the drug formulation and manufacturing business unit of Elan, following the approval of the merger by Alkermes, Inc. shareholders on Sept. 8, 2011.

17 Sep 2011

Researchers discuss how decision neuroscience hopes to advance understanding of brain

Although still a young field, research in "decision neuroscience" has exploded in the last decade, with scientists beginning to decipher what exactly is happening in our brains when we are making choices, whether big or small.

16 Sep 2011

New report finds improvements in hospital performance

Meanwhile, Reuters reports on the quality of weekend care at stroke centers and nursing homes are trying to reduce their use of powerful antipsychotic drugs for patients with dementia.

16 Sep 2011

Schizophrenia News and Research

Latest Schizophrenia News and Research

Jails are holding increasing numbers of mentally ill

AstraZeneca settles SEROQUEL XR patent infringement litigation

New report finds little evidence to support off-label use of atypical antipsychotics

Experts to explore implications of mental disorders at 12th EMBL | EMBO conference

UCSF neuroscientist wins PECASE award for research into addiction

Benefits and harms vary among atypical antipsychotics for off-label use

BioLineRx's BL-1020 Phase IIb EAGLE trial data on schizophrenia to be presented at ECSR

Afraxis to participate in NIH's Therapeutics for Rare and Neglected Disease Program

High consumption of caffeinated coffee appears to reduce risk of depression in women

Common genetic variants linked to schizophrenia and bipolar disorder

Cornell researchers identify how T. gondii controls host's immune system

Common DNA variations contribute to schizophrenia, bipolar disorder

Scientists discover common genetic variants associated with schizophrenia and bipolar disorder

Aestus to develop ATx09-002 for treatment of neuropathic pain

Alkermes establishes business operations in Ireland

Researchers confirm strong bidirectional relation between epilepsy, schizophrenia

Landmark international study confirms common genetic contribution to mental illness

Alkermes completes merger with Elan Drug Technologies

Researchers discuss how decision neuroscience hopes to advance understanding of brain

New report finds improvements in hospital performance

Forensics and toxicology - Industry Focus eBook eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Schizophrenia News and Research

Latest Schizophrenia News and Research

Forensics and toxicology - Industry Focus eBook eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in